Cynapsus Therapeutics Inc Stock

Stocks

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
06-03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
05-20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
24-03-11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
24-01-29	CoTec Holdings Outlines Key Targets For 2024	MT
24-01-03	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
23-10-10	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
23-10-10	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
23-10-02	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
23-09-14	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
23-09-14	CoTec Holdings, Mkango To Form US Joint Venture	MT
23-06-30	Kings Chapel Increases Stake In CoTec Holdings	MT

05-06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
16-08-31	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
16-08-29	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
16-08-15	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
16-08-12	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
ARGENX SE	+0.68%	+5.92%	+77.86%	+136.97%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.26%	+92.31%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-10.57%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+440.44%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	-0.37%	+5.67%	+48.82%	-2.41%	19.69B
GENMAB A/S	-0.29%	+9.78%	+43.90%	-29.12%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+186.15%	+347.42%	16.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.80%	+17.42%	+45.15%	-	14.84B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+193.33%	14.04B
Average	+1.61%	+8.57%	+55.66%	+146.05%	27.28B
Weighted average by Cap.	+1.77%	+6.47%	+59.20%	+136.02%